Recent developments in the management of T-cell precursor acute lymphoblastic leukemia/lymphoma

Adele K Fielding; Lalita Banerjee; David I Marks

doi:10.1007/s11899-012-0123-4

Recent developments in the management of T-cell precursor acute lymphoblastic leukemia/lymphoma

Adele K Fielding, Lalita Banerjee, David I Marks

The Hull York Medical School

Research output: Contribution to journal › Review article › peer-review

Abstract

T-cell acute lymphoblastic leukemia and T-cell lymphoblastic lymphoma are uncommon disorders classified together by the World Health Organization classification as "T-lymphoblastic leukemia/lymphoma." This review gives an overview on the treatment of these aggressive but curable T cell malignancies in adult patients, in order to highlight current developments. The most interesting and relevant developments are in our understanding of the genetics of T-ALL/LBL and how the genetics relate to clinical outcome. These studies will inform clinicians as to which targeted novel agents may be of value and how patients may be best risk-stratified to receive them.

Original language	English
Pages (from-to)	160-9
Number of pages	10
Journal	Current hematologic malignancy reports
Volume	7
Issue number	2
DOIs	https://doi.org/10.1007/s11899-012-0123-4
Publication status	Published - Jun 2012

Keywords

Antineoplastic Agents/therapeutic use
Disease Management
Enzyme Inhibitors/therapeutic use
Humans
Phenotype
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma/genetics
Prognosis
Stem Cell Transplantation/methods
T-Lymphocytes/immunology

Access to Document

10.1007/s11899-012-0123-4

Cite this

@article{3568289ef84b406690bdfbff3a96738e,

title = "Recent developments in the management of T-cell precursor acute lymphoblastic leukemia/lymphoma",

abstract = "T-cell acute lymphoblastic leukemia and T-cell lymphoblastic lymphoma are uncommon disorders classified together by the World Health Organization classification as {"}T-lymphoblastic leukemia/lymphoma.{"} This review gives an overview on the treatment of these aggressive but curable T cell malignancies in adult patients, in order to highlight current developments. The most interesting and relevant developments are in our understanding of the genetics of T-ALL/LBL and how the genetics relate to clinical outcome. These studies will inform clinicians as to which targeted novel agents may be of value and how patients may be best risk-stratified to receive them.",

keywords = "Antineoplastic Agents/therapeutic use, Disease Management, Enzyme Inhibitors/therapeutic use, Humans, Phenotype, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma/genetics, Prognosis, Stem Cell Transplantation/methods, T-Lymphocytes/immunology",

author = "Fielding, {Adele K} and Lalita Banerjee and Marks, {David I}",

year = "2012",

month = jun,

doi = "10.1007/s11899-012-0123-4",

language = "English",

volume = "7",

pages = "160--9",

journal = "Current hematologic malignancy reports",

issn = "1558-8211",

publisher = "Springer Science + Business Media",

number = "2",

}

TY - JOUR

T1 - Recent developments in the management of T-cell precursor acute lymphoblastic leukemia/lymphoma

AU - Fielding, Adele K

AU - Banerjee, Lalita

AU - Marks, David I

PY - 2012/6

Y1 - 2012/6

N2 - T-cell acute lymphoblastic leukemia and T-cell lymphoblastic lymphoma are uncommon disorders classified together by the World Health Organization classification as "T-lymphoblastic leukemia/lymphoma." This review gives an overview on the treatment of these aggressive but curable T cell malignancies in adult patients, in order to highlight current developments. The most interesting and relevant developments are in our understanding of the genetics of T-ALL/LBL and how the genetics relate to clinical outcome. These studies will inform clinicians as to which targeted novel agents may be of value and how patients may be best risk-stratified to receive them.

AB - T-cell acute lymphoblastic leukemia and T-cell lymphoblastic lymphoma are uncommon disorders classified together by the World Health Organization classification as "T-lymphoblastic leukemia/lymphoma." This review gives an overview on the treatment of these aggressive but curable T cell malignancies in adult patients, in order to highlight current developments. The most interesting and relevant developments are in our understanding of the genetics of T-ALL/LBL and how the genetics relate to clinical outcome. These studies will inform clinicians as to which targeted novel agents may be of value and how patients may be best risk-stratified to receive them.

KW - Antineoplastic Agents/therapeutic use

KW - Disease Management

KW - Enzyme Inhibitors/therapeutic use

KW - Humans

KW - Phenotype

KW - Precursor T-Cell Lymphoblastic Leukemia-Lymphoma/genetics

KW - Prognosis

KW - Stem Cell Transplantation/methods

KW - T-Lymphocytes/immunology

U2 - 10.1007/s11899-012-0123-4

DO - 10.1007/s11899-012-0123-4

M3 - Review article

C2 - 22476945

SN - 1558-8211

VL - 7

SP - 160

EP - 169

JO - Current hematologic malignancy reports

JF - Current hematologic malignancy reports

IS - 2

ER -